Contents
Foreword
List of Contributors
Section 1: Basic Scientific Foundation
Editors: John D. Kelly, Hardev Pandha, Maria Shevchuk, Karl-Dietrich Sievert, and Atsushi Takenaka
1. Development, Applied and Surgical Anatomy of the Prostate
Anthony J. Costello and Niall M. Corcoran
2. Molecular Biology and Prostate Cancer
Greg L. Shaw and David E. Neal
3. Endocrine Mechanisms, Androgen Receptor and Carcinogenesis, Hormone Escape
Kaustubh Datta and Donald Tindall
4. Molecular Mechanisms of Castrate Resistant Prostate Cancer
Francois Lamoureux, Amina Zoubeidi, and Martin E. Gleave
5. Immunologic Aspects of Prostate Cancer
Christine Galustian, Oussama Elhage, Richard Smith, and Prokar Dasgupta
6. Stem Cells in Carcinogenesis of the Prostate
Shi-Ming Tu and Sue-Hwa Lin
7. Murine Models of Prostate Cancer
Eric C. Kauffman, Casey K. Ng, and Carrie Rinker-Schaeffer
8. Prostate Cancer and the Metabolic Syndrome
Stephen EM Langley and Jenny P. Nobes
9. Inflammation and Cancer of the Prostate
Sonya Vasto, Emilio Italiano, Vitale Miceli, and Giuseppe Carruba
10. HIV and Prostate Cancer
Matthew S. Wosnitzer, Jennifer J. Ahn, and Franklin C. Lowe
11. Prostate Cancer Genetics
Sashi S. Kommu, Samuel Bishara, and Stephen M. Edwards
12. Gene Expression Profiling and Somatic Genome Changes
Michael Ittmann
13. The Proteomic Approach to Prostate Cancer
Sashi S. Kommu and Emanual Petricoin
14. Epigenetic Changes in Prostate Cancer
William G. Nelson, Michael C. Haffner, Angelo M. De Marzo, and Srinivasan Yegnasubramanian
15. Biomarkers of Potential Therapeutic Value
Hideaki Miyake, Atsushi Takenaka, and Masato Fujisawa
16. Prostate Tissue Banking
Harveer Dev, Prasanna Sooriakumaran, and Ashutosh Tewari
17. Molecular Imaging in Diagnostics
Casey Ng, Eric Kauffman, and Hossein Jadvar
18. Molecular Risk Profiling
Neil E. Martin
19. Premalignant Lesions of the Prostate
Daniel M. Berney and Anne Y. Warren
20. The Pathology of Prostatic Carcinoma
Maria Shevchuk and Brian D. Robinson
21. The Pathology of Non-Epithelial Tumors of the Prostate
Maria Shevchuk and Brian D. Robinson
22. Neuroendocrine Prostate Cancer
Himisha Beltran, Juan Miguel Mosquera, and Mark A. Rubin
Section 2: Epidemiology, Screening, and Chemoprevention
Editors: Neil Fleshner, Cynthia Kuk, William Nelson, and Alexandre Zlotta
23. Epidemiology of Prostate Cancer
Ankur M. Manvar, Raj S. Pruthi, Eric. M. Wallen, and Matthew E. Nielsen
24. Racial Disparities and the Global Picture
James E. Ferguson III, Matthew Nielsen, Eric Wallen, Raj Pruthi
25. Natural History of Prostate Cancer
Paul K. Hegarty and Nicholas J. Hegarty
26. Population-Based Health Systems as a Foundation for Prostate Cancer Control Research: The Cancer Research Network
Mark C. Hornbrook and Joan Holup
27. Screening for Prostate Cancer
David R. Yates and John B. Anderson
28. Next Generation Screening Tests
Jack A. Schalken and Rizal Hamid
29. Diet and Prostate Cancer: A Holistic Approach to Management
Philippa J. Cheetham and Aaron E. Katz
30. Estrogens in Prostate Cancer
Giuseppe Carruba
31. Vitamin D and Prostate Cancer
Naomi Smith and Alejandro Nolazco
32. The Role of 5a-Reductase Inhibitors (5-ARIs) in Prostate Cancer Chemoprevention
David Margel and Neil Fleshner
33. Other Pharmaceutical Agents in the Chemoprevention of Prostate Cancer
Vivekanandan Kumar
Section 3: Diagnosis and Staging
Editors: Peter Carroll and Gary Dorfman
34. Early-Detection and Patient Risk Stratification in Prostate Cancer
Rajesh Nair, John Withington, Sukanya Ghosh, and Alastair Henderson
35. Tumor Markers
Diederick Duijvesz and Guido Jenster
36. Prostate Specific Membrane Antigen-Based Diagnostics
Joseph Osborne, Scott T. Tagawa, Shankar Vallabhajosula, Stanley J. Goldsmith, and Neil H. Bander
37. Prostate Specific Membrane Antigen-Based Therapeutics
Scott T. Tagawa, Joseph Osborne, Shankar Vallabhajosula, Stanley J. Goldsmith, and Neil H. Bander
38. Presentation and Symptomatology of Prostate Cancer
Agnieszka Michael and Hardev Pandha
39. The Role of Ultrasonography
Suzanne van den Heuvel, Paul C.M.S. Verhagen, and Chris H. Bangma
40. The Use of Magnetic Resonance Imaging in the Management of Prostate Cancer
Matthieu Durand, Aude Fregeville, Naveen Gumpeni, Abhishek Srivastava, Prasanna Sooriakumaran, Siobhan Gruschow, Niyati Harneja, Kristin M. Saunders, Jean Amiel, and Ashutosh K. Tewari
41. The Role of Functional Magnetic Resonance Imaging Techniques
Pieter J. De Visschere, Gert O. De Meerleer, Nicolaas Lumen, and Geert M. Villeirs
42. Prostate Biopsy
Paras B. Singh, Caroline M. Moore, and Mark Emberton
43. The Staging of Prostate Cancer
Benjamin J. Challacombe and Giles Rottenberg
44. Nuclear Medicine in Prostate Cancer
Vinayaka Moorthy Majuran, Vidhiya Vinayakamoorthy, and Derek Svasti-Salee
45. Nanotechnology and Prostate Cancer
Sashi S. Kommu, Lidong Qin, Louis Brousseau, Amrith Rao, Philippe Grange, and Mauro Ferrari
Section 4: Risk Assessment and Decision-Making Strategies for Localized Prostate Cancer
Editor: Matthew Cooperberg
46. Disease Risk Stratification
Alistair Henderson
47. Nomograms in Prostate Cancer
Carvell T. Nguyen and Michael W. Kattan
48. Comparative Effectiveness of Treatment Alternatives for Localized Prostate Cancer
Matthew R. Cooperberg
Section 5: Management of Localized Disease
Editors: Prokar Dasgupta, Alex Mottrie, Abhay Rane, Joseph Smith, Datta Wagle, and Peter Wiklund
49. Radical Treatment for Localized Disease: An Overview of Options and Strategies for Decision Making
Joseph A. Smith, Jr.
50. Quality of Life and Management of Localized Disease
Andreas E. Nilsson, Gunnar Steineck, and N. Peter Wiklund
51. Active Surveillance for Favorable-Risk Prostate Cancer
Nathan Lawrentschuk and Laurence Klotz
52. Anesthesia for Robotic-Assisted Prostatectomy
Vinod Malhotra and Peter M. Fleischut
53. Retropubic Radical Prostatectomy: The Technique
Hein Van Poppel and Steven Joniau
54. Retropubic Radical Prostatectomy: The Results
Wolfgang Horninger and Jasmine Bektic
55. Radical Perineal Prostatectomy
Rolf Gillitzer and Joachim W. Thüroff
56. Laparoscopic Radical Prostatectomy: The Technique
Christopher Eden and Anthony Hutton
57. Laparoscopic Radical Prostatectomy: The Results
Evangelos Liatsikos, Odysseas Andrikopoulos, Panagiotis Kallidonis, and Jens-Uwe Stolzenburg
58. Robotic Assisted Radical Prostatectomy: The Technique
Sameer Chopra, Abhishek Srivastava, Prasanna Sooriakumaran, and Ashutosh K. Tewari
59. Lymph Node Dissection in Prostate Cancer Surgery
Aaron Bernie, Douglas S. Scherr, and Michael P. Herman
60. External Beam Radiotherapy for Low Risk Prostate Cancer
Gert De Meerleer, Piet Ost, Geert Villeirs, Nicolaas Lumen, and Valérie Fonteyne
61. Prostate Brachytherapy: Low Dose Rate
Peter Grimm
62. Prostate Brachytherapy: High Dose Rate
Carl Salembier and Peter Hoskin
63. Intensity Modulated Radiotherapy
Bridget F. Koontz, Devon Godfrey, and W. Robert Lee
64. Proton Beam Therapy and Novel Radiotherapeutic Approaches to the Treatment of Prostate Cancer
Jeffrey J. Meyer, Jordan A. Holmes, and Ronald C. Chen
65. Prostate Cryotherapy
Mohamed Ismail, Shwan Ahmed, and John Davies
66. Focal Therapies for Localized Prostate Cancer
Louise Dickinson, Hashim U. Ahmed, and Mark Emberton
Section 6: Failure and Management of Recurrent, Locally Advanced, and Advanced Disease
Editors: Andrew Armstrong, Ronald Chen, Richard Stock, and John Sylvester
67. Biochemical Failure in Prostate Cancer
Tian Zhang and Andrew Z. Wang
68. The Phenomenon of PSA Bounce After Radiation Therapy
Peter Acher and Rick Popert
69. Management of Locally Recurrent Disease
Piet Ost, Valérie Fonteyne, Pieter De Visschere, Nicolaas Lumen, and Gert De Merleer
70. Management of High Risk/Locally Advanced Disease
Valérie Fonteyne, Piet Ost, Nicolaas Lumen, Geert Villeirs, and Gert De Meerleer
71. Radiotherapy Plus Hormonal Therapy
Jordan A. Holmes and Ronald Chen
72. Watchful Waiting in Advanced Prostate Cancer
Maria Carmen Mir and Nathan Lawrentschuk
73. Androgen and Androgen Receptor Directed Therapy as Initial Treatment for Prostate Cancer
Bruce Montgomery and Peter S. Nelson
74. Hormone-Based Therapies for Castration Resistant Prostate Cancer
Elahe A. Mostaghel and Peter S. Nelson
75. Toxicity of Androgen Deprivation Therapy in Hormone Sensitive Prostate Cancer
Naveed H. Akhtar, Elan S. Diamond, Nicole Eiseler, and Scott T. Tagawa
76. Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer
Robyn J. Macfarlane, Chris Hovens, Niall M. Corcoran, and Kim N. Chi
77. Immunotherapy
Nicola E. Annels and Hardev Pandha
78. Bone Health: Prevention of Skeletal Related Events and Palliative Care
Jean-Baptiste Lattouf and Fred Saad
Section 7: Outcomes and Complications After Treatment
Editors: Mark Emberton, Brent Hollenbeck, and Tom Lue
79. Assessment of Treatment Outcomes Following Prostate Cancer Therapy
Paul Cathcart and Mark Emberton
80. Urinary Incontinence
Ted A. Skolarus
81. Erectile Dysfunction
Maarten Albersen and Tom F. Lue
82. Immediate/Early Surgical Complications
Thomas J. Walton and Declan G. Murphy
83. Population-Based Outcomes Following Treatment of Clinically-Localized Prostate Cancer
Blake Evans and Scott M. Gilbert
84. Management of Radiation Adverse Effects
Seth A. Strope
85. Management of Complications Following Minimally Invasive Prostate Cancer Therapy
Paul Cathcart and Anthony J. Costello
Section 8: Management of Emergencies and Palliative Care
Editors: Steven A. Kaplan and Alexis E. Te
86. Prostate Cancer Emergencies
Bethan C. Hickerton, Mohamed Abdulmajed, Manit Arya, and Iqbal S. Shergill
87. Management of Bone Metastases
Keen Hun Tai and Farshad Foroudi
88. Pain Relief in Metastatic Cancer
Odette Spruyt and Natasha Michael
89. The Psycho-Social Impact of Prostate Cancer
Addie Wooten and Heather Siddons
90. Nursing Issues in Prostate Cancer
Helen Crowe
